Tirzepatide cuts COPD exacerbations and mortality in T2D patients vs. SGLT2i/DPP-4i.
Tirzepatide versus other glucose-lowering therapies and risk of COPD exacerbations in patients with comorbid type 2 diabetes: a retrospective cohort study.
Abstract
Tirzepatide significantly reduced COPD exacerbations (HR 0.73 vs SGLT2i, HR 0.72 vs DPP-4i) and all-cause mortality in patients with comorbid type 2 diabetes and COPD.
TitrateLab articles covering Tirzepatide
Written by TitrateLab, separately from the study summarized above.
